Experience in the use of vaccine Gam-Kovid-Vak-M for the prevention of COVID-19 in children

The goal is to evaluate the tolerability and effectiveness of the domestic vector vaccine Gam-Covid-Vak-M in children aged 12—17 years, adherence to vaccination of adolescents and parents to improve work on the prevention of COVID-19. Materials and methods. A retrospective analysis of the medical records of 115 children aged 12—17 years who were vaccinated in 2022 with the Gam-COVID-Vac-M vaccine in two children's polyclinics in St. Petersburg was carried out. Additional information was collected through telephone interviews. A cross-sectional anonymous online survey of adolescents aged 15—17 was also conducted to study awareness of COVID-19 and adherence to vaccination. Results. Only 23.5% of those vaccinated were at risk for severe and complicated COVID-19. Parents showed low adherence to vaccination against COVID-19 — 71.3% vaccinated themselves and 73.1% considered it necessary to protect the child. Only in 14.1% of cases, a teenager aged 15—17 made the decision to be vaccinated. According to 76.9% of adolescents, COVID-19 is a dangerous disease, while 55.6% consider vaccination unnecessary, mainly due to ineffective protection and the possibility of complications. Nevertheless, side effects after the first and second components of Gam-COVID-Vac-M were observed in 24.3% and 24.2%, respectively, which is 4 times less than with foreign vaccines. Systemic and local reactions were observed on days 1—2 after immunization. All manifestations were mild or moderate and resolved within 1—2 days on average. Serious adverse events were not registered. The effectiveness of the vaccine was 97.4%. Conclusion. Preliminary results indicate good tolerance and efficacy of the domestic vaccine Gam-COVID-Vac-M.

1. Chernova T.M., Pavlova E.B., Timchenko V.N., Ermakova E.O., Uskova S.Yu. et al. Clinical and epidemiological characteristics and effectiveness of antiviral therapy for COVID-19 in children: The experience of the first year of the pandemic. Acta biomedica scientifica. 2021; 6(6—2):18—28. (In Russ). DOI: 10.29413/ABS.2021-6.6-2.3

2. Brewster RC, Parsons C, Laird-Gion J, Hilker S, Irwin M, Sommerschield A, et al. COVID-19-associated croup in children. Pediatrics. 2022. 149:e2022056492. DOI: 10.1542/peds.2022-056492

3. Levy N, Koppel JH, Kaplan O, Yechiam H, Shahar-Nissan K, Cohen NK, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022. 327:2452—4. DOI: 10.1001/jama.2022.8025

4. Fernandes DM, Oliveira CR, Guerguis S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. J Pediatr. 2021; 230: e10:23—31. DOI:10.1016/j.jpeds.2020.11.016

5. Chernova T.M., Timchenko V.N., Barakina E.V., Zherebtsova A.A., Gusarova N.S. et al. Outcome of COVID-19 in children: results of a 12-month follow-up. Journal Infectology. 2022; 14(2): 96—106. (In Russ.). DOI: https://doi.org/10.22625/2072-6732-2022-14-2-96-106

6. Osmanov I.M., Spiridonova E., Bobkova P., et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the 2 ISARIC Global follow-up protocol: A prospective cohort study. Eur Respir J. 2022; 59(2): ID 2101341 DOI: 10.1183/13993003.01341-2021

7. Torjesen I. COVID-19: omicron variant is linked to steep rise in hospital admissions of very young children. BMJ. 2022; 376:o110. DOI: 10.1136/bmj.o110

8. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the omicron and Delta variants in children younger than 5 years in the US. JAMA Pediatr. 2022. 176:811—3. DOI: 10.1001/jamapediatrics.2022.0945

9. CDC. COVID-19 Vaccination. https://www.cdc.gov/vaccines/ covid-19/info-by-product/pfizer/index.html

10. SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong. http://www.sinovac.com/news/shownews.php?id=1501&lang=en

11. Gam-KOVID-Vak-M Kombinirovannaya vektornaya vakcina dlya profilaktiki koronavirusnoj infekcii, vyzyvaemoj SARS-CoV-2. Instrukciya po primeneniyu. (In Russ.).

12. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19. Interim guidance.18 August 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3

13. Interim recommendations for use of the Pfizer—BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. 18 August 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1

14. Choi UI, Pang Yi, Zheng Yu, Tang PK, Hu Hao, Ung COL. Parents' intention for their children to receive COVID-19 vaccine: Implications for vaccination program in Macao. Front Pediatr. 2022; 10:978661. DOI: 10.3389/fped.2022.978661

15. Galanis P, Vraka I, Siskou O, Konstantakopoulou O, Katsiroumpa A, Kaitelidou D. Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: a systematic review and meta-analysis. Prev Med. 2022. 157:106994. DOI: 10.1016/j.ypmed.2022.106994

16. Kharit SM, Timchenko VN, Chernova TM, Bulina OV. Vaccination of children against coronavirus infection caused by SARS-CoV-2. Pediatr. 2023;14(1):5—14. (In Russ.). DOI: https://doi.org/10.17816/PED1415-14

17. Moiseeva K.E., Alekseeva A.V. Osnovnye prichiny otkazov ot vakcinacii. Social'nye aspekty zdorov'ya naseleniya [setevoe izdanie]. 2019; 65(5): 9. (In Russ.). DOI: 10.21045/2071-5021-2019-65-5-9]

18. Facciolà A, Visalli G, Orlando A, Bertuccio MP, Spataro P, Squeri R, Picerno I, Di Pietro A. Vaccine hesitancy: An overview on parents’ opinions about vaccination and possible reasons of vaccine refusal. J. Public Health Res. 2019; 8(1):1436. DOI: 10.4081/jphr.2019.1436.

19. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events. CDC, COVID-19. Vaccination. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html

20. The Moderna COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events. CDC, COVID-19. Vaccination. https://www.cdc.gov/vaccines/covid-19/info-byproduct/moderna/reactogenicity.html

21. Kharit S.M., Fridman I.V. mRNA-based vaccines for the prevention of coronavirus infection. Journal Infectology. 2022;14(1):5—19. (In Russ.) https://doi.org/10.22625/2072-6732-2022-14-1-5-19]

22. Zimmermann P, Pittet LF, Finn А, Pollard AJ, Curtis N. Should children be vaccinated against COVID-19? Arch Dis Child. 2022;107:e1. DOI:10.1136/archdischild-2021-323040

23. Gargano JW, Wallace M, Hadler SC, Langley G, Suet JR et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(27):977—982. DOI:10.15585/mmwr.mm7027e2

24. Gill, JR., Tashjian, R., Duncanson, E. Autopsy histopathologic cardiac findings in two adolescents following the second COVID-19 vaccine dose. Arch Pathol Lab Med. 2022; 146(8):925—929. DOI: 10.5858/arpa.2021-0435-SA

25. Kraaijeveld, SR, Gur-Arie R, Jamrozik, E. Against COVID-19 vaccination of healthy children. Bioethics. 36(6):687—698. https://doi.org/10.1111/bioe.13015

26. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon Ju. et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239—250. DOI: 10.1056/NEJMoa2107456

27. Ali K, Berman G, Zhou H, Deng W, Faughnan V, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021; 385(24):2241—2251. DOI: 10.1056/NEJMoa2109522

28. Sadeghi S, Kalantari Ya, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, Valizadeh R. Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2—21 years old: A Systematic Review and Meta-analysis. J Clin Virol. 2022; 153:105196. DOI: 10.1016/j.jcv.2022.105196.

29. Choi UI, Pang Yi, Zheng Yu, Tang PK, Hu Hao, Ung COL. Parents' intention for their children to receive COVID-19 vaccine: Implications for vaccination program in Macao. Front Pediatr. 2022; 10:978661. DOI: 10.3389/fped.2022.978661

30. Ermolenko KD, Kharit SM, Ruleva AA, et al. Establishing a Dialogue with a Patient on Vaccination (Scientific Review). Epidemiology and Vaccinal Prevention. 2021; 20(1):114—124. (In Russ.). doi: 10.31631/2073-3046-2021-20-1-114-124